|Synonyms||Dithranol; 1,8-Dihydroxyanthrone; Anthracene-1,8,9-triol; NSC 43970; NSC 629313|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||Faint yellow to yellow powder.|
|Solubility||Soluble in acetone.|
|Identity||Determined by NMR.|
|Declaration||Manufactured by Chemodex.|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
Anthralin is a leukotriene biosynthesis inhibitor. It inhibits LTB4 ω-oxidation and disrupts mitochondria function. Anthralin is used in the treatment of psoriasis, as a fungicide, in the treatment of ringworm infections and in chronic dermatoses. It accumulates in mitochondria where it interferes with the supply of energy to the cell, probably by the oxidation of dithranol releasing free radicals. This impedes DNA replication and so slows the excessive cell division that occurs in psoriatic plaques. Numerous studies have demonstrated anti-proliferative and anti-inflammatory effects of anthralin on psoriatic and normal skin. It is also used as matrix substance for MALDI-MS (matrix-assisted laser desorption ionization MS).
(1) R.E. Ashton, et al.; J. Am. Acad. Dermatol. 9, 173 (1983) | (2) J.M. Schröder; J. Invest. Dermatol. 87, 624 (1986) | (3) C.E. Orfanos, et al.; Drugs 34, 459 (1987) (Review) | (4) L. Kemeny, et al.; Skin Pharmacol. 3, 1 (1990) | (5) K. Müller; Biochem. Pharmacol. 53, 1215 (1997) (Review) | (6) K. Pavithran; Indian J. Dermatol. Venereol. Leprol. 67, 104 (2001) | (7) C.H. Le, et al.; Anal. Chem. 84, 8391 (2012) | (8) C. Ronpirin & T. Tencomnao; Genet. Mol. Res. 11, 412 (2012) | (9) S.E. George, et al.; J. Pharm. Pharmacol. 65, 552 (2013)